| Price | 18.88 |
| Price Change Today | -$0.13 (-0.68%) |
| P&P rating | ![]() |
| Zacks Rank | 3 - HOLD |
| Open Price | $19.00 |
| Previous Close | $19.01 |
| Daily Range | $18.72 - $19.12 |
| 52-Week Range | $12.29 - $22.40 |
| Volume | 870,254 |
| Seatlle Genetic develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, the company have assembled a portfolio of drug candidates targeted to many types of human cancers. The company utilizes its monoclonal antibody-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. The company is testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers. | |




Comments: 3 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment